Partnership Expands Animal Enzyme Solutions

The partnership is the result of the focus Novus has on generating enzyme solutions to optimize nutrition—and the resulting feed costs—in a number of production livestock species, as well as companion animals with the highest performing quality solutions.

"Our partnership with Verenium will allow us to work together to develop and commercialize a suite of new enzyme products for the global animal nutrition and health market," notes Thad Simons, President and Chief Executive Officer of Novus International. "These new enzyme products will give us the ability to offer new solutions to the performance challenges our customers face."

Novus International, a company with more than 20 years experience in the animal nutrition market, is deeply committed to the enzyme and fermentation business.

"The enzyme business is perfectly aligned with Novus’ mission to make a clear difference in sustainably meeting the growing global demand for animal nutrition," says Gary Hayen, Novus Global Business Director, Fermentation Products Business. "This partnership brings together the synergy of both the biotechnology and animal nutrition fields. We really believe we’ve only started to scratch the surface of the industry’s demand for enzymes and are excited to provide innovative solutions, powered by Verenium, to meet the market’s needs."

"Verenium’s approach to product development is very innovative and based on the highest standards of science," adds Mr Simons. "This partnership is a natural alignment and we expect to deliver great results to our industry by working together." Combining the strengths of two industry leaders builds on Novus' existing enzyme offering and knowledge of animal nutrition by offering the strength of Verenium’s world class enzyme biotechnology . The continued expansion of Novus’s enzyme product offering in collaboration with Verenium will add to the track record of success that enzymes have in providing critical solutions in the poultry and livestock sectors.

"We are extremely enthusiastic about our partnership with Novus, the potential opportunity it represents for the continued development of our pipeline and for Verenium to become a more active participant in the animal health and nutrition marketplace with our suite of high-performance enzyme products," said James Levine, President and Chief Executive Officer at Verenium. "Novus brings world-class leadership and experience launching products in this market, and with our combined skills, we look forward to working closely as partners to commercialize a series of market-leading products over the coming years."